Mereo BioPharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Mereo BioPharma GroupDer Gewinn des Unternehmens wird voraussichtlich um 20.4% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 44.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 27.4% pro Jahr wachsen.

Wichtige Informationen

-18.1%

Wachstumsrate der Gewinne

29.6%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	27.7%
Wachstumsrate der Einnahmen	47.2%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	21 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0A9G - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	22	-65	-33	N/A	2
12/31/2025	16	-33	-27	N/A	5
12/31/2024	14	-16	-13	N/A	5
3/31/2024	10	-26	-21	-20	N/A
12/31/2023	10	-29	-22	-21	N/A
9/30/2023	9	-32	-33	-33	N/A
6/30/2023	9	-33	-43	-42	N/A
3/31/2023	N/A	-42	-46	-46	N/A
12/31/2022	N/A	-42	-47	-49	N/A
9/30/2022	N/A	-31	-42	-43	N/A
6/30/2022	N/A	-23	-40	-41	N/A
3/31/2022	24	-4	-25	-26	N/A
12/31/2021	49	17	-8	-7	N/A
9/30/2021	49	-10	-9	-8	N/A
6/30/2021	50	-37	-10	-10	N/A
3/31/2021	25	-131	-23	-25	N/A
12/31/2020	N/A	-224	-36	-39	N/A
9/30/2020	N/A	-198	-35	-37	N/A
6/30/2020	N/A	-177	-34	-36	N/A
3/31/2020	N/A	-111	-46	-47	N/A
12/31/2019	N/A	-46	-61	-61	N/A
9/30/2019	N/A	-41	-50	-50	N/A
6/30/2019	N/A	-40	-45	-45	N/A
3/31/2019	N/A	-41	-38	-38	N/A
12/31/2018	N/A	-41	-30	-29	N/A
9/30/2018	N/A	-42	-41	-39	N/A
6/30/2018	N/A	-44	-51	-48	N/A
3/31/2018	N/A	-50	-52	-48	N/A
12/31/2017	N/A	-52	N/A	-43	N/A
9/30/2017	N/A	-50	N/A	-41	N/A
6/30/2017	N/A	-47	N/A	-39	N/A
3/31/2017	N/A	-41	N/A	-37	N/A
12/31/2016	N/A	-35	N/A	-37	N/A
6/30/2016	N/A	-39	N/A	-25	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0A9G wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0A9G wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0A9G wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0A9GDie Einnahmen des Unternehmens (44.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0A9GDie Einnahmen des Unternehmens (44.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von 0A9G in 3 Jahren voraussichtlich hoch sein wird

Mereo BioPharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Forecast to breakeven in 2025

Recent updates

Mereo BioPharma Group plc has filed a Follow-on Equity Offering in the amount of $49.999887 million.

Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study

Mereo BioPharma Group plc, Annual General Meeting, May 23, 2024

Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)

Ultragenyx Pharmaceutical Inc. Announces Data from the Dose- Selection Phase 2/3 Orbit Study

Mereo BioPharma Group plc Presents Phase 2 Data from “ASTRAEUS” Trial of Its Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease at the 2023 American Thoracic Society International Conference

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Less than half of directors are independent

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo Biopharma Group plc Announces Board Changes

Rubric Capital Management LP Comments on Mereo BioPharma Group Plc Updated Operating Plan

Mereo BioPharma Group plc Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Less than half of directors are independent

Less than half of directors are independent

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Rubric Capital Management LP Issues a Letter to the Shareholders of Mereo BioPharma Group plc

Mereo Biopharma Group plc Reports Clinical Update and Interim Biomarker Analysis Presented At Esmo 2022 from Activate Phase 1B/2 Open Label Study of Etigilimab (Anti-Tigit Antibody Mph-313) Plus Nivolumab (Anti-Pd-1 Antibody) in Solid Tumors

Investor sentiment deteriorated over the past week

Rubric Capital Management LP Delivers a Letter to Mereo BioPharma Group

Mereo BioPharma Group plc Announces Board Changes

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Astrazeneca Reportedly Considering Take over Offer for Mereo

Investor sentiment improved over the past week

Rubric Capital Sends Letter to Mereo BioPharma

Mereo BioPharma Group plc to Present Data Update for the Phase 1B/2 Study (Activate) of Etigilimab and Nivolumab At 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan

High number of new directors

High number of new directors

Rubric Capital Discloses its Views on Mereo BioPharma

Mereo BioPharma Receives Notification of Nasdaq Minimum Bid Price Deficiency

Mereo BioPharma Group plc Announces Board Changes

Mereo BioPharma Group plc Announces Positive Top-Line Efficacy and Safety Data from “Astraeus” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Emphysema

Investor sentiment deteriorated over the past week

Mereo BioPharma Group plc Announces Appointment of Anne Hyland to Board of Directors

The University of Alabama at Birmingham and Mereo BioPharma Group plc, Announces Positive Top-Line Results from “Costa” A Phase 1B/2 Trial of Alvelestat in Hospitalized Patients with Covid-19 Respiratory Disease

Mereo Biopharma Group plc to Present Biomarker Data from Phase 1B/2 Investigator-Sponsored Trial of Alvelestat in Bronchiolitis Obliterans Syndrome at the ASH Annual Meeting

High number of new directors

High number of new directors

Mereo BioPharma Announces Positive Desmosine Biomarker Data from an Interim Analysis of an Investigator Initiated Study of alvelestat in Bronchiolitis Obliterans Syndrome (BOS)

Forecast to breakeven in 2025

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken